Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Christian Frank, Michael Hundemer, Anthony D. Ho, Hartmut Goldschmidt & Mathias Witzens-Harig. (2008) Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leukemia & Lymphoma 49:4, pages 779-785.
Read now
Read now
Philipp Schütt, Dieter Brandhorst, Werner Stellberg, Miriam Poser, Peter Ebeling, Siemke Müller, Ulrike Buttkereit, Bertram Opalka, Monika Lindemann, Hans Grosse-Wilde, Siegfried Seeber, Thomas Moritz & Mohammad R. Nowrousian. (2006) Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leukemia & Lymphoma 47:8, pages 1570-1582.
Read now
Read now
Daniel M-Y. Sze, Ross D. Brown, Edna Yuen, John Gibson, Joy Ho, Maria Raitakari, Antony Basten, Douglas E. Joshua & Barbara Fazekas de St Groth. (2003) Clonal Cytotoxic T Cells in Myeloma. Leukemia & Lymphoma 44:10, pages 1667-1674.
Read now
Read now
Articles from other publishers (23)
Claudio Fozza & Maurizio Longinotti. (2013) T-cell receptor repertoire usage in hematologic malignancies. Critical Reviews in Oncology/Hematology 86:3, pages 201-211.
Crossref
Crossref
Isabelle Herth, Mathias Witzens-Harig, Philipp Beckhove, Dirk Hose, Tobias Meissner, Brigitte Neuber, Melanie Engelhardt, Jürgen Haas, Kai Neben, Anthony D. Ho, Bernard Klein, Hartmut Goldschmidt & Michael Hundemer. (2013) Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. Experimental Hematology 41:3, pages 231-240.
Crossref
Crossref
Angela Oranger, Claudia Carbone, Maddalena Izzo & Maria Grano. (2013) Cellular Mechanisms of Multiple Myeloma Bone Disease. Clinical and Developmental Immunology 2013, pages 1-11.
Crossref
Crossref
Ross Brown, P. Joy Ho, John Gibson & Douglas Joshua. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma
3
24
.
Lenka Tesarova, Irena Koutna, Zdenek Koristek & Martin Klabusay. (2011) Multiple myeloma patients at peripheral blood stem cell harvest: Restricted usage of TCR beta variable families. Clinical Immunology 138:1, pages 67-76.
Crossref
Crossref
Güllü GörgünElisabetta CalabreseEnder SoydanTeru HideshimaGiulia PerroneMadhavi BandiDiana CirsteaLoredana SantoYiguo HuYu-Tzu TaiSabikun NaharNaoya MimuraClaire FabreNoopur Raje, Nikhil Munshi, Paul RichardsonKenneth C. Anderson. (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:17, pages 3227-3237.
Crossref
Crossref
Jia LiDaniel M.-Y. SzeRoss D. BrownMark J. CowleyWarren Kaplan, Sui-Lin Mo, Shihong YangEsther AkliluKarieshma KabaniYen S. LohTetsuo YamagishiYuling Chen, P. Joy HoDouglas E. Joshua. (2010) Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood 115:17, pages 3580-3588.
Crossref
Crossref
Maria Grano, Giacomina Brunetti & Silvia Colucci. (2009) Immunomodulation of Multiple Myeloma Bone Disease. Clinical Reviews in Bone and Mineral Metabolism 7:4, pages 293-300.
Crossref
Crossref
Martha Q. Lacy, Sumithra Mandrekar, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, David Dingli, Mark Litzow, Peter Wettstein, Douglas Padley, Brian Kabat, Dennis Gastineau, S. Vincent Rajkumar & Morie A. Gertz. (2009) Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American Journal of Hematology 84:12, pages 799-802.
Crossref
Crossref
M. Alcoceba, L. Marín, A. Balanzategui, M. E. Sarasquete, P. Martín-Jiménez, M. C. Chillón, R. Corral, E. Pérez-Persona, F. J. Fernández-Calvo, J. M. Hernández, J. Bladé, J. J. Lahuerta, M. González, J. F. San Miguel & R. García-Sanz. (2008) The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens 71:6, pages 548-551.
Crossref
Crossref
Masih Ostad, Margareta Andersson, Astrid Gruber & Anne Sundblad. (2008) Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood 111:5, pages 2725-2732.
Crossref
Crossref
Madhav V. Dhodapkar. 2009. Myeloma Therapy. Myeloma Therapy
143
166
.
Jon S. Fukumoto & Jason Gotlib. (2006) A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance. American Journal of Hematology 81:11, pages 870-874.
Crossref
Crossref
Guzi Li, Michael Hundemer, Sonja Wolfrum, Anthony D. Ho, Hartmut Goldschmidt & Mathias Witzens-Harig. (2006) Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). Annals of Hematology 85:9, pages 583-590.
Crossref
Crossref
Maria Monne, Giovanna Piras, Angelo Palmas, Luigi Arru, Marco Murineddu, Giancarlo Latte, Annalisa Noli & Attilio Gabbas. (2004) Cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) gene polymorphism and susceptibility to non‐Hodgkin's lymphoma. American Journal of Hematology 76:1, pages 14-18.
Crossref
Crossref
D Hönemann, P Kufer, M M Rimpler, M Chatterjee, S Friedl, F Riecher, K Bommert, B Dörken & R C Bargou. (2004) A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. Leukemia 18:3, pages 636-644.
Crossref
Crossref
M. Raitakari, R. D. Brown, J. Gibson & D. E. Joshua. (2003) T cells in myeloma. Hematological Oncology 21:1, pages 33-42.
Crossref
Crossref
Daniel M.-Y. SzeGillian GiesajtisRoss D. BrownMaria RaitakariJohn GibsonJoy HoAlan G. BaxterBarbara Fazekas de St GrothAntony BastenDouglas E. Joshua. (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28− compartment. Blood 98:9, pages 2817-2827.
Crossref
Crossref
Sara Mariani, Marta Coscia, Jos Even, Silvia Peola, Myriam Foglietta, Mario Boccadoro, Luca Sbaiz, Gabriella Restagno, Alessandro Pileri & Massimo Massaia. (2002) Severe and long‐lasting disruption of T‐cell receptor diversity in human myeloma after high‐dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology 113:4, pages 1051-1059.
Crossref
Crossref
Chengyun Zheng, DeRen Huang, Li Liu, Magnus Björkholm, Göran Holm, Qing Yi & Anne Sundblad. (2001) Cytotoxic T‐lymphocyte antigen‐4 microsatellite polymorphism is associated with multiple myeloma. British Journal of Haematology 112:1, pages 216-218.
Crossref
Crossref
Belinda PopeRoss D. BrownJohn GibsonEdna YuenDoug Joshua. (2000) B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96:4, pages 1274-1279.
Crossref
Crossref
Belinda PopeRoss D. BrownJohn GibsonEdna YuenDoug Joshua. (2000) B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96:4, pages 1274-1279.
Crossref
Crossref
Maria Raitakari, Ross D. Brown, Daniel Sze, Edna Yuen, Lisa Barrow, Margaret Nelson, Belinda Pope, Warren Esdale, John Gibson & Douglas E. Joshua. (2000) T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. British Journal of Haematology 110:1, pages 203-209.
Crossref
Crossref